Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.

ABSTRACT:

Background

Phosphatase and tensin homolog (PTEN) loss is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer. However, the clinical value of PTEN as a biomarker in these patients is controversial. We sought to determine whether the benefit of traditional biomarkers testing is improved by the analysis of PTEN status for the identification of high-risk breast cancer.

Methods

A cohort of 608 patients with breast cancer was included in this study. Based on the expression on the neoplastic cells compared to the normal internal controls by immunohistochemistry (IHC), cases were classified as PTEN-low (PTEN-L) or PTEN-retained (PTEN-WT). The former constituted the study group, while the latter the control group. Analysis of gene expression was

SUBMITTER: Sajjadi E 

PROVIDER: S-EPMC8555186 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature